Bayer AG ((BAYRY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bayer AG is conducting an observational study titled ‘ESTeeM: Evaluation of Sleep Disturbances in Menopause’ to explore how menopause affects women’s sleep and their current treatment methods. The study aims to understand the impact of menopause-related sleep disturbances on women’s quality of life and assess the need for new treatment options.
Intervention/Treatment: The study does not involve any new interventions. Instead, it observes women who continue their standard care treatments for sleep disturbances associated with menopause.
Study Design: This is a prospective cohort observational study. Data will be collected electronically from participants’ health records, questionnaires, and smartwatches over a 28-day period, without requiring any additional visits or tests.
Study Timeline: The study began on November 13, 2024, with primary data collection expected to complete by May 2025. The latest update was submitted on July 25, 2025, indicating ongoing recruitment.
Market Implications: This study could influence Bayer’s stock performance by highlighting potential gaps in menopause-related treatments, potentially leading to new product developments. Investors should watch for updates as the study progresses, noting that competitors in women’s health may also be affected by these findings.
The study is ongoing, with further details available on the ClinicalTrials portal.